Cravit Should be Administered with Caution in The Following Patients: Patients with impaired renal function; those exposed to direct sunlight; with known or suspected central nervous system disorder that may predispose to seizures or lower the seizure threshold; diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (especially, sulfonylureas or with insulin preparations).
Patients with a history of hypersensitivity to quinolone antibiotics.
Patients with serious heart diseases eg, arrhythmia and ischemic heart disease (prolonged QT may occur); patients with uncorrected electrolyte imbalance (eg, hypokalemia, hypomagnesemia) and patients receiving class 1A and III antiarrhythmic agents.
Patients with myasthenia gravis (symptoms may be exacerbated).
Effects on the Ability to Drive or Operate Machinery: Neurologic adverse effects eg, dizziness, vertigo and somnolence may occur. Therefore, patients should be instructed that such neurologic adverse effects may impair the patient's ability to concentrate and react, and therefore may constitute a risk in situation where these abilities are of special importance (eg, activities at high place, driving a car or operating machinery).
Use in the Elderly: The pharmacokinetic properties of levofloxacin in younger adults and elderly adults do not differ significantly when creatinine clearance is taken into consideration. However, since Cravit is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.